Alnylam Pharmaceuticals, Inc. (ALNY)
Company Info
| ISIN | US02043Q1076 |
|---|---|
| CUSIP | 02043Q107 |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | May 28, 2004 |
Highlights
| Market Cap | $34.69B |
|---|---|
| EPS (TTM) | -$2.61 |
| PEG Ratio | -0.49 |
| Total Revenue (TTM) | $2.01B |
| Gross Profit (TTM) | $1.79B |
| EBITDA (TTM) | -$146.13M |
| Year Range | $141.98 - $304.39 |
| Target Price | $306.62 |
| Short % | 3.30% |
| Short Ratio | 4.60 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: ALNY vs. SPY, ALNY vs. VOO, ALNY vs. SNY
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Alnylam Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Alnylam Pharmaceuticals, Inc. had a return of 40.51% year-to-date (YTD) and 62.99% in the last 12 months. Over the past 10 years, Alnylam Pharmaceuticals, Inc. had an annualized return of 11.58%, while the S&P 500 benchmark had an annualized return of 11.39%, indicating that Alnylam Pharmaceuticals, Inc. performed slightly bigger than the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 40.51% | 25.45% |
| 1 month | -5.41% | 2.91% |
| 6 months | 81.86% | 14.05% |
| 1 year | 62.99% | 35.64% |
| 5 years (annualized) | 24.44% | 14.13% |
| 10 years (annualized) | 11.58% | 11.39% |
Monthly Returns
The table below presents the monthly returns of ALNY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -9.67% | -12.62% | -1.09% | -3.68% | 3.11% | 63.71% | -2.28% | 10.62% | 4.70% | -3.07% | 40.51% | ||
| 2023 | -4.73% | -15.44% | 4.63% | -0.56% | -7.12% | 2.66% | 2.87% | 1.24% | -10.47% | -14.29% | 10.84% | 13.77% | -19.46% |
| 2022 | -18.86% | 14.72% | 3.45% | -18.29% | -5.72% | 15.94% | -2.61% | 45.50% | -3.15% | 3.55% | 6.43% | 7.73% | 40.14% |
| 2021 | 15.78% | -1.58% | -4.67% | -0.39% | 0.96% | 19.39% | 5.56% | 12.57% | -6.27% | -15.49% | 15.19% | -7.74% | 30.48% |
| 2020 | -0.33% | 2.50% | -7.49% | 20.99% | 2.71% | 9.49% | -1.59% | -9.00% | 9.77% | -15.54% | 5.64% | 0.05% | 12.85% |
| 2019 | 14.57% | 1.76% | 9.94% | -4.40% | -24.42% | 7.46% | 6.93% | 4.00% | -0.33% | 7.86% | 35.05% | -1.68% | 57.96% |
| 2018 | 2.31% | -7.56% | -0.88% | -20.63% | 5.23% | -0.99% | -3.54% | 29.13% | -28.65% | -8.10% | 0.91% | -10.17% | -42.61% |
| 2017 | 6.81% | 29.13% | -0.76% | 4.59% | 22.13% | 21.85% | 3.74% | 3.61% | 37.05% | 3.70% | 10.42% | -5.57% | 239.34% |
| 2016 | -26.77% | -15.04% | 7.17% | 6.80% | 6.98% | -22.63% | 22.69% | 2.60% | -2.96% | -47.48% | 23.23% | -14.66% | -60.23% |
| 2015 | -3.27% | 8.21% | 2.85% | -2.44% | 28.68% | -8.56% | 6.31% | -19.24% | -21.91% | 6.96% | 21.07% | -9.53% | -2.95% |
| 2014 | 30.11% | -2.89% | -17.36% | -26.23% | 19.71% | 6.54% | -14.33% | 28.73% | 12.10% | 18.75% | 8.42% | -3.53% | 50.86% |
| 2013 | 32.22% | -1.82% | 2.87% | -1.72% | 27.89% | 1.21% | 48.94% | 12.19% | 23.57% | -10.00% | 6.23% | 5.07% | 252.33% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current risk-adjusted rank of ALNY is 79, placing it in the top 21% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Alnylam Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alnylam Pharmaceuticals, Inc. was 83.58%, occurring on Oct 3, 2011. Recovery took 439 trading sessions.
The current Alnylam Pharmaceuticals, Inc. drawdown is 10.51%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -83.58% | Oct 10, 2007 | 1004 | Oct 3, 2011 | 439 | Jul 3, 2013 | 1443 |
| -77.36% | Jun 23, 2015 | 347 | Nov 3, 2016 | 257 | Nov 10, 2017 | 604 |
| -57.81% | Mar 21, 2018 | 193 | Dec 24, 2018 | 374 | Jun 19, 2020 | 567 |
| -52.18% | Jun 10, 2004 | 46 | Aug 16, 2004 | 100 | Jan 6, 2005 | 146 |
| -47.61% | Jan 14, 2014 | 72 | Apr 28, 2014 | 126 | Oct 24, 2014 | 198 |
Volatility
Volatility Chart
The current Alnylam Pharmaceuticals, Inc. volatility is 10.71%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Alnylam Pharmaceuticals, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |